CCXI ChemoCentryx Inc

Price (delayed)

$19.21

Market cap

$1.34B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.78

Enterprise value

$1.34B

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's ...

Highlights
The EPS has plunged by 98% from the previous quarter
ChemoCentryx's net income has plunged by 94% from the previous quarter

Key stats

What are the main financial stats of CCXI
Market
Shares outstanding
69.9M
Market cap
$1.34B
Enterprise value
$1.34B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.06
Price to sales (P/S)
62.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
61.8
Earnings
Revenue
$21.61M
EBIT
-$120.07M
EBITDA
-$115.99M
Free cash flow
-$102.25M
Per share
EPS
-$1.78
Free cash flow per share
-$1.47
Book value per share
$4.74
Revenue per share
$0.31
TBVPS
$6.7
Balance sheet
Total assets
$467.67M
Total liabilities
$137.4M
Debt
$69.73M
Equity
$330.27M
Working capital
$261.75M
Liquidity
Debt to equity
0.21
Current ratio
5.73
Quick ratio
5.65
Net debt/EBITDA
0.06
Margins
EBITDA margin
-536.8%
Gross margin
100%
Net margin
-568.5%
Operating margin
-562.3%
Efficiency
Return on assets
-24.3%
Return on equity
-33.2%
Return on invested capital
-26.2%
Return on capital employed
-29.1%
Return on sales
-555.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CCXI stock price

How has the ChemoCentryx stock price performed over time
Intraday
5.55%
1 week
16.57%
1 month
22.12%
1 year
-63.58%
YTD
-68.98%
QTD
43.47%

Financial performance

How have ChemoCentryx's revenue and profit performed over time
Revenue
$21.61M
Gross profit
$21.61M
Operating income
-$121.51M
Net income
-$122.86M
Gross margin
100%
Net margin
-568.5%
The company's operating income has shrunk by 95% QoQ
ChemoCentryx's net income has plunged by 94% from the previous quarter
ChemoCentryx's gross profit has plunged by 72% YoY and by 69% from the previous quarter
The revenue has shrunk by 72% YoY and by 69% QoQ

Growth

What is ChemoCentryx's growth rate over time

Valuation

What is ChemoCentryx stock price valuation
P/E
N/A
P/B
4.06
P/S
62.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
61.8
The EPS has plunged by 98% from the previous quarter
CCXI's P/B is 74% below its 5-year quarterly average of 15.0 and 54% below its last 4 quarters average of 8.3
The company's equity fell by 22% YoY and by 9% QoQ
The price to sales (P/S) is 99% higher than the 5-year quarterly average of 29.6 and 12% higher than the last 4 quarters average of 52.7
The revenue has shrunk by 72% YoY and by 69% QoQ

Efficiency

How efficient is ChemoCentryx business performance
The ROA has plunged by 136% YoY and by 101% from the previous quarter
The company's return on equity has shrunk by 106% QoQ and by 69% YoY
The return on invested capital has dropped by 77% since the previous quarter and by 38% year-on-year

Dividends

What is CCXI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CCXI.

Financial health

How did ChemoCentryx financials performed over time
The quick ratio has declined by 37% year-on-year and by 20% since the previous quarter
The current ratio has contracted by 36% YoY and by 20% from the previous quarter
The debt is 79% lower than the equity
The debt to equity has soared by 75% YoY and by 11% from the previous quarter
The debt is up by 35% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.